Organisation paid for research Program year 2025 Source: CMS Open Payments

Tennessee Retina PC

Neither a doctor nor a teaching hospital

Research payments

$10,367,453

2,731 payments

Through program year 2025, Tennessee Retina PC is reported as receiving $10,367,453 in research payments, across 2,731 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$4,564,385	1,891
2024	Research	$1,733,428	492
2023	Research	$1,352,818	183
2022	Research	$2,003,896	124
2021	Research	$380,078	22
2020	Research	$96,970	3
2019	Research	$235,879	16

Breakdown

Who paid Research payments · program years 2019–2025

Genentech, Inc. $5,021,830 472 payments
Regeneron Pharmaceuticals, Inc. $2,942,500 1,724 payments
Ocular Therapeutix, Inc. $1,290,294 108 payments
Apellis Pharmaceuticals, Inc. $552,366 134 payments
EyePoint Pharmaceuticals US, Inc. $200,621 3 payments
Novartis Pharmaceuticals Corporation $148,418 4 payments
F. Hoffmann-La Roche AG $91,205 259 payments
Astellas Pharma Global Development $70,861 9 payments
ANI Pharmaceuticals, Inc. $28,802 8 payments
Hoffmann-La Roche Limited $9,907 3 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 3b Single-Arm Study of Aflibercept 8 mg in Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) $1,824,084 1,106 payments
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration $1,290,294 108 payments
Study of the Port Delivery System With Ranibizumab in Patients With Diabetic MacUlar Edema $924,422 42 payments
Port Delivery System of Ranibizumab Extension Study $918,200 60 payments
A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema $820,968 523 payments
Mad to Assess the Safety Tolerability and PK PD in Namd Patients $626,829 61 payments
A Phase III Study to Investigate Ro7200220 in Patients With Uveitic MacUlar Edema $495,117 51 payments
Phase 2 of Ro7171009 in Ga $323,565 36 payments
A Phase III Multicenter Observation Comparator Study of the Efficacy Safety and Pharmacokinetics $284,717 44 payments
Belvedere $273,860 8 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.